ycliper

Популярное

Музыка Кино и Анимация Автомобили Животные Спорт Путешествия Игры Юмор

Интересные видео

2025 Сериалы Трейлеры Новости Как сделать Видеоуроки Diy своими руками

Топ запросов

смотреть а4 schoolboy runaway турецкий сериал смотреть мультфильмы эдисон
Скачать

Generic Drugs Forum 2022 – Day 1, Session 2

Автор: U.S. Food and Drug Administration

Загружено: 2022-05-09

Просмотров: 1294

Описание: FDA presents on the Current State of Generic Drugs and offers practical advice, presenting case studies, and taking a deep dive into the abbreviated new drug application assessment program. Presentations focus on topics such as the pre-ANDA program, generic drug metrics, post-market safety, pre-approval inspections, and global generic drug affairs. Includes Q&A session and a moderated panel discussion.


4:54 – ANDA Program Annual Public Stats and What they Mean: Office of Generic Drugs (OGD)
15:49 – ANDA Program Annual Public Stats and What they Mean: Office of Regulatory Operations (ORO)
35:07 - ANDA Program Annual Public Stats and What they Mean: Office of Generic Drug Policy (OGDP)
47:00 - ANDA Program Annual Public Stats and What they Mean: Office of Lifecycle Drug Products (OLDP)
56:22 – Questions & Panel Discussion

Presenters and Panel:

Iilun Murphy
Deputy Director, Clinical & Regulatory Affairs, OGD | CDER

Robert Berger - Analytics Team
David Holovac - Analytics Team
Russell Storms - Associate Director for Analytics
Edward (Ted) Sherwood – Director
ORO, OGD | CDER

Andrew Coogan
Lieutenant Commander, U.S. Public Health Service
Division of Legal and Regulatory Support (DLRS), OGDP | CDER

Derek Smith
Deputy Director, OPMA | Office of Pharmaceutical Quality (OPQ) | CDER

Geoffrey Wu
Commander, U.S. Public Health Service
Deputy Director, OLDP | OPQ | CDER

For slides and additional information: https://www.fda.gov/drugs/news-events...

-------------------- 
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.   

Upcoming Training - https://www.fda.gov/cdersbia
SBIA Listserv - https://public.govdelivery.com/accoun...
SBIA 2022 Playlist -    • 2022 CDER Small Business and Industry Assi...  
SBIA LinkedIn -   / cder-small-business-and-industry-assistance  
SBIA Training Resources - https://www.fda.gov/cdersbialearn
Twitter -   / fda_drug_info  
Email - [email protected]
Phone - (301) 796-6707 I (866) 405-5367

Не удается загрузить Youtube-плеер. Проверьте блокировку Youtube в вашей сети.
Повторяем попытку...
Generic Drugs Forum 2022 – Day 1, Session 2

Поделиться в:

Доступные форматы для скачивания:

Скачать видео

  • Информация по загрузке:

Скачать аудио

Похожие видео

Generic Drugs Forum 2022 – Day 1, Session 3

Generic Drugs Forum 2022 – Day 1, Session 3

FDA Grand Rounds - Adopting Large Language Models for Regulatory Review

FDA Grand Rounds - Adopting Large Language Models for Regulatory Review

FDA Expert Panel on Testosterone Replacement Therapy for Men

FDA Expert Panel on Testosterone Replacement Therapy for Men

FDA Grand Rounds - Statistical Considerations for Drug Development in Rare Disease

FDA Grand Rounds - Statistical Considerations for Drug Development in Rare Disease

Medical Device Quality Management System Regulation Risk Management

Medical Device Quality Management System Regulation Risk Management

Generic Drugs Forum 2022 – Day 1, Session 1

Generic Drugs Forum 2022 – Day 1, Session 1

FDA Grand Rounds - Advancing Real World Evidence in FDA Regulatory Decision Making

FDA Grand Rounds - Advancing Real World Evidence in FDA Regulatory Decision Making

FDA-USP-AAM | D1S3 - Industry’s Engagement in USP’s Standards-Setting Process

FDA-USP-AAM | D1S3 - Industry’s Engagement in USP’s Standards-Setting Process

FDA Grand Rounds - Postmarket Regulation of Cosmetic Products: The Who, What, When, Why, and How

FDA Grand Rounds - Postmarket Regulation of Cosmetic Products: The Who, What, When, Why, and How

FDA Grand Rounds - Anti biofilm Technologies for Enhancing the Safety of Medical Device Surfaces

FDA Grand Rounds - Anti biofilm Technologies for Enhancing the Safety of Medical Device Surfaces

Generic Drugs Forum 2022 – Day 1, Session 4

Generic Drugs Forum 2022 – Day 1, Session 4

Medical Device Quality Management System Regulation Design and Development

Medical Device Quality Management System Regulation Design and Development

FDA Grand Rounds - Forensic Proteomics Applied to FDA Regulated Products

FDA Grand Rounds - Forensic Proteomics Applied to FDA Regulated Products

FDA-USP-AAM | D1S1 – FDA's Participation in USP-NF Revision Process – Challenges and Solutions

FDA-USP-AAM | D1S1 – FDA's Participation in USP-NF Revision Process – Challenges and Solutions

FDA Celebrates 120 Years

FDA Celebrates 120 Years

Conversations on Cancer – Perspectives on Cancer Care Decision-Making Among Older Adults

Conversations on Cancer – Perspectives on Cancer Care Decision-Making Among Older Adults

Roundtable on PMTA Submissions for ENDS Products

Roundtable on PMTA Submissions for ENDS Products

FDA Grand Rounds - Antibody Glycosylation Insights for High Quality Biotherapeutics

FDA Grand Rounds - Antibody Glycosylation Insights for High Quality Biotherapeutics

FDA-USP-AAM | D1S2 – Strengthening Your Compendial Strategy

FDA-USP-AAM | D1S2 – Strengthening Your Compendial Strategy

Public Meeting: Reauthorization of the Biosimilar User Fee Act

Public Meeting: Reauthorization of the Biosimilar User Fee Act

© 2025 ycliper. Все права защищены.



  • Контакты
  • О нас
  • Политика конфиденциальности



Контакты для правообладателей: [email protected]